昆明医科大学学报2017，Vol.38Issue(2)：78-81,4.
左西孟旦治疗高龄慢性心衰急性失代偿患者的安全性及疗效
Efficacy and Safety of Levosimendan in Treatment of Advanced Sged Patients with Scute Fecompensated Vhronic Heart Failure
摘要
Abstract
Objective To observe the safety and clinical effect of the application of levosimendanin to advanced aged patients with acute decompensated chronic heart failure.Method 45 acute decompensated chronic heart failure patients more than 85 years old with low cardiac output (Cardiac function:Ⅲ-Ⅳ level,left ventricular ejective fraction ≤ 40％ and high blood plasma NT-ProBNP ≥ 500 ug/L),experimental group (23 cases) were given levosimendan treatment,and control group (22 cases) were given dobutamine treatment.Vital signs,general clinical status,LVEF,and blood plasma NT-ProBNP changes were monitored before and after drug use.Results No statistical difference between the two groups was observed before treatment (P＞0.05).At different time points after treatment,compared with the control group,the experimental group were statistically significant (P＜0.05 or P＜0.01) in relieving clinical status of heart failure,raising LVEF and reducing blood plasma NT-ProBNP.Incidence of adverse reactions is 22.7％ in the experimental group and 42.9％ in the control group,no serious adverse reactions in either group.Conclusion Levosimendan can improve heart failure symptoms,raise heart function level in advanced aged patients with acute decompensated chronic heart failure.It is safe and effective with no serious adverse reactions.关键词
高龄/慢性心衰急性失代偿/左西孟旦Key words
Aged/Acute decompensated chronic heart failure/Levosimendan分类
医药卫生引用本文复制引用
时晔,牛小群,曹宇,李会..左西孟旦治疗高龄慢性心衰急性失代偿患者的安全性及疗效[J].昆明医科大学学报,2017,38(2):78-81,4.基金项目
云南省科技厅-昆明医科大学应用基础研究联合专项基金资助项目(2015UH00417) （2015UH00417）
